Masahito Katahira

Prof. Dr. Masahito Katahira

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2008 in Hormone Research in Paediatrics
Verified
Journal Article
Closed access
PDF file
MKMasahito Katahira
Masahito Katahira
TIToshiaki Ishiguro
Toshiaki Ishiguro
SSSatoko Segawa
Satoko Segawa
KKKaoru Kuzuya-Nagao
Kaoru Kuzuya-Nagao
IHIwao Hara
Iwao Hara
TNTsuneo Nishisaki
Tsuneo Nishisaki
Aim: This study aims at clarifying the human leukocyte antigen haplotypes and genotypes conferring susceptibility or resistance to type 1 diabetes in the Japanese population. Methods: The frequencies of human leukocyte antigen DR-DQ haplotypes and genotypes were compared between 83 type 1 diabetic patients, except for fulminant type 1 diabetes, and control subjects in the Japanese population. The patients were divided by onset age into four groups (ages 5–14, 15–29, 30–49, and 50–71 years); the haplotype frequency was compared between each group. Results: The frequencies of DRB1*0405-DQB1*0401 (DR4), DRB1*0802-DQB1*0302 (DR8), DRB1*0901-DQB1*0303 (DR9), and DRB1*1302-DQB1* 0604 (DR13) haplotypes were significantly higher in the patients than in the control subjects. The frequencies of DRB1* 1501-DQB1*0602 and DRB1*1502-DQB1*0601 haplotypes were significantly lower in the patients than in the controls. The frequencies of DR4/8, DR4/13, DR9/9, and DR9/13 genotypes were significantly higher in the patients than in the control subjects. The DR13 haplotype was the most frequent haplotype in the age group 30–49 years, whereas the other haplotypes but DR13 were the most frequent in the other age groups. Conclusion: DR4, DR8, DR9, and DR13 haplotypes confer susceptibility to type 1 diabetes in Japanese patients.

1 September 2009 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
MKMasahito Katahira
Masahito Katahira
HMHarumi Maeda
Harumi Maeda
TTTakahiro Tosaki
Takahiro Tosaki
SSSatoko Segawa
Satoko Segawa

1 April 2021 in Human Immunology
Verified
Journal Article
Closed access
MKMasahito Katahira
Masahito Katahira
HOHidetada Ogata
Hidetada Ogata
HTHiromi Takashima
Hiromi Takashima
TITakahiro Ito
Takahiro Ito
YHYuichi Hodai
Yuichi Hodai
SNShizuka Nakamura
Shizuka Nakamura

1 August 2010 in Human Immunology
Verified
Journal Article
Closed access
MKMasahito Katahira
Masahito Katahira
SSSatoko Segawa
Satoko Segawa
HMHarumi Maeda
Harumi Maeda
YYYoshinori Yasuda
Yoshinori Yasuda

11 July 2018 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
MKMasahito Katahira
Masahito Katahira
HOHidetada Ogata
Hidetada Ogata
TITakahiro Ito
Takahiro Ito
TMTsutomu Miwata
Tsutomu Miwata
MGMegumi Goto
Megumi Goto
HTHiromi Takashima
Hiromi Takashima
The presence of antiglutamic acid decarboxylase antibody (GADA) is required for the diagnosis of slowly progressive type 1 diabetes (SPT1D). We examined the factors influencing GADA determination by radioimmunoassay (GADA-RIA) and by enzyme-linked immunosorbent assay (GADA-ELISA). Sixty patients with SPT1D and 154 patients with type 2 diabetes were examined by both GADA-RIA and GADA-ELISA and for the presence of autoimmune thyroid disease (AITD). We compared the clinical characteristics of these patients based on the positivity or negativity of GADA-RIA and GADA-ELISA, and the existence or nonexistence of AITD. Thirty of 60 (50.0%) GADA-RIA-positive patients were GADA-ELISA negative, whereas none of the 154 GADA-RIA-negative patients were GADA-ELISA positive. Concomitant AITD was significantly less in patients with GADA-RIA and without GADA-ELISA and was significantly more in patients with GADA-RIA and GADA-ELISA. In GADA-RIA-positive patients, there was no significant difference in the GADA-RIA titer among the GADA-ELISA-negative patients with and without AITD, and the GADA-ELISA-positive patients without AITD; whereas the frequency of insulin deficiency was significantly higher in the patients with AITD and/or GADA-ELISA than in those without AITD and GADA-ELISA. Examination of GADA-ELISA and AITD in GADA-RIA-positive patients might be useful in predicting insulin deficiency in these patients.

31 July 2022 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
MKMasahito Katahira
Masahito Katahira
SMShigeaki Moriura
Shigeaki Moriura
SOSatoko Ono
Satoko Ono